Literature DB >> 11668217

Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.

U M Zanger1, J Fischer, S Raimundo, T Stüven, B O Evert, M Schwab, M Eichelbaum.   

Abstract

Variable expression and function of the cytochrome P4502D6 (CYP2D6) leads to distinct phenotypes termed ultrarapid (UM), extensive (EM), intermediate (IM) and poor metabolizer (PM). Whereas the PM phenotype is known to be caused by two null-alleles leading to absence of functional CYP2D6 protein, the large variability among individuals with functional alleles remained largely unexplained. In this study, we systematically investigated 76 liver biopsies from individuals with known sparteine metabolic ratios (MRS) for the relationships between CYP2D6 genotype, microsomal protein expression, bufuralol 1'-hydroxylase activity and in-vivo phenotype. Average CYP2D6 protein levels ranged from undetectable in PMs (MRS > 20) to 2.6 +/- 2.7 pmol/mg microsomal protein in IMs (1.2 < MRS< 20), 7.6 +/- 4.7 in EMs (0.2 < MRS < 1.2) and 23.8 +/- 7.7 in UMs (MRS < 0.2), respectively. Analysis with respect to genotype demonstrated gradually increased expression and function for individuals with no, one, two or three functional gene copies per genome. The recently discovered -1584 C/G promoter polymorphism was identified as another major factor for expression and function with the mutant [-1584G] promoter type being consistently associated with significantly higher expression than [-1584C]. To investigate functional differences between the detected variant protein forms CYP2D6.1, 2D6.2, 2D6.9 and 2D6.10, we expressed them recombinantly in insect cells. The most significant difference was a decrease in the relative P450 holoprotein content of all allelic forms, including the common functional variant 2D6.2, in comparison to 2D6.1, whereas only modest Km changes were observed. Taken together, these data provide further insight into the complex mechanisms that govern the highly variable expression and function of CYP2D6.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11668217     DOI: 10.1097/00008571-200110000-00004

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  57 in total

1.  The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.

Authors:  Janet K Coller; Niels Krebsfaenger; Kathrin Klein; Karin Endrizzi; Renzo Wolbold; Thomas Lang; Andreas Nüssler; Peter Neuhaus; Ulrich M Zanger; Michel Eichelbaum; Thomas E Mürdter
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

Review 2.  Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism.

Authors:  Timothy S Tracy; Amarjit S Chaudhry; Bhagwat Prasad; Kenneth E Thummel; Erin G Schuetz; Xiao-Bo Zhong; Yun-Chen Tien; Hyunyoung Jeong; Xian Pan; Laura M Shireman; Jessica Tay-Sontheimer; Yvonne S Lin
Journal:  Drug Metab Dispos       Date:  2015-12-17       Impact factor: 3.922

3.  Frequency of undetected CYP2D6 hybrid genes in clinical samples: impact on phenotype prediction.

Authors:  John Logan Black; Denise L Walker; Dennis J O'Kane; Maria Harmandayan
Journal:  Drug Metab Dispos       Date:  2011-10-17       Impact factor: 3.922

4.  CYP2D6 genotype and phenotype determination in a Mexican Mestizo population.

Authors:  Marisol López; Jorge Guerrero; Helgi Jung-Cook; María Elisa Alonso
Journal:  Eur J Clin Pharmacol       Date:  2005-10-26       Impact factor: 2.953

Review 5.  Genetics and psychopharmacology: prospects for individualized treatment.

Authors:  Charles U Nnadi; Joseph F Goldberg; Anil K Malhotra
Journal:  Essent Psychopharmacol       Date:  2005

Review 6.  The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.

Authors:  Norbert Thuerauf; Jens Lunkenheimer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08       Impact factor: 5.270

7.  Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders.

Authors:  Julia Kirchheiner; Cristina Rodriguez-Antona
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

8.  The CYP4502D6 *4 and *6 alleles are the molecular genetic markers for drug response: implications in colchicine non-responder FMF patients.

Authors:  Sinem Yalcıntepe; Ozturk Ozdemır; Coskun Sılan; Filiz Ozen; Ahmet Uludag; Ferhan Candan; Fatma Sılan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-02-03       Impact factor: 2.441

Review 9.  Transcriptional Regulation of CYP2D6 Expression.

Authors:  Xian Pan; Miaoran Ning; Hyunyoung Jeong
Journal:  Drug Metab Dispos       Date:  2016-10-03       Impact factor: 3.922

10.  Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia.

Authors:  Yanfeng Wang; Li Zhou; Catherine Dutreix; Elisabeth Leroy; Qi Yin; Venkat Sethuraman; Gilles-Jacques Riviere; Ophelia Q P Yin; Horst Schran; Zhi-Xiang Shen
Journal:  Br J Clin Pharmacol       Date:  2008-04-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.